Table 1.
Frequency of adults (ages ≥ 20 years at AML diagnosis) with diagnostically confirmed first primary AML diagnosed 2001–2018 (followed through 2019) overall and for those reported to have received initial chemotherapy for AML, according to age, race and ethnicity, sex, calendar year period of diagnosis, and AML subgroups, SEER-17.a
| Characteristic | All adults with AML (N = 40,155) |
% adults treated with initial chemotherapy (70.9%) |
Adults treated with initial chemotherapy (N = 28,473) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All adults treated with initial chemotherapy |
Age (years) |
AML subgroup |
||||||||||
| 20–39 |
40–59 |
60–74 |
75–84 |
≥85 |
APL |
CBF AML |
Antecedent C/T |
All other AML |
||||
| No. | % | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Age at diagnosis, years | ||||||||||||
| 20–39 | 4978 | 92.2 | 4592 (16.1) | – | – | – | – | – | 1086 (34.8) | 347 (32.0) | 111 (5.6) | 3048 (13.7) |
| 40–59 | 10,407 | 88.9 | 9253 (32.5) | – | – | – | – | – | 1298 (41.6) | 407 (37.5) | 496 (25.0) | 7052 (31.7) |
| 60–74 | 12,781 | 76.7 | 9798 (34.4) | – | – | – | – | – | 602 (19.3) | 253 (23.3) | 888 (44.8) | 8055 (36.2) |
| 75–84 | 8428 | 47.2 | 3978 (14.0) | – | – | – | – | – | 131 (4.2) | 66 (6.1) | 407 (20.5) | 3374 (15.2) |
| ≥85 | 3561 | 23.9 | 852 (3.0) | – | – | – | – | – | 24 (0.8) | 12 (1.1) | 81 (4.1) | 735 (3.3) |
| Race and ethnicity | ||||||||||||
| Non-Hispanic | ||||||||||||
| White | 27,649 | 68.9 | 19,038 (66.9) | 2243 (48.8) | 5825 (63.0) | 7245 (73.9) | 3038 (76.4) | 687 (80.6) | 1740 (55.4) | 660 (60.8) | 1458 (73.5) | 15,180 (68.2) |
| Black | 3283 | 73.6 | 2417 (8.5) | 533 (11.6) | 941 (10.2) | 692 (7.1) | 211 (5.3) | 40 (4.7) | 343 (10.9) | 92 (8.5) | 124 (6.3) | 1858 (8.3) |
| Asian | 3234 | 75.0 | 2425 (8.5) | 460 (10.0) | 818 (8.8) | 742 (7.6) | 337 (8.5) | 68 (8.0) | 247 (7.9) | 99 (9.1) | 176 (8.9) | 1903 (8.5) |
| Pacific Islander | 265 | 74.0 | 196 (0.7) | 44 (1.0) | 84 (0.9) | 53 (0.5) | 15 (0.4) | 0 (0) | 28 (0.9) | 13 (1.2) | 13 (0.7) | 142 (0.6) |
| Other/unspecifiedb | 298 | 67.1 | 200 (0.7) | 43 (0.9) | 72 (0.8) | 62 (0.6) | 17 (0.4) | <10 (−) | 31 (1.0) | 23 (2.1) | 10 (0.5) | 136 (0.6) |
| Hispanic | 5426 | 77.3 | 4197 (14.7) | 1269 (27.6) | 1513 (16.4) | 1004 (10.2) | 360 (9.0) | 51 (6.0) | 752 (23.9) | 198 (18.2) | 202 (10.2) | 3045 (13.7) |
| Sex | ||||||||||||
| Males | 21,853 | 72.1 | 15,751 (55.3) | 2301 (50.1) | 5034 (54.4) | 5708 (58.3) | 2301 (57.8) | 407 (47.8) | 1611 (51.3) | 624 (57.5) | 1239 (62.5) | 12,277 (55.1) |
| Females | 18,302 | 69.5 | 12,722 (44.7) | 2291 (49.9) | 4219 (45.6) | 4090 (41.7) | 1677 (42.2) | 445 (52.2) | 1530 (48.7) | 461 (42.5) | 744 (37.5) | 9987 (44.9) |
| Calendar year of diagnosis | ||||||||||||
| 2001–2006 | 12,826 | 64.4 | 8259 (29.0) | 1362 (29.7) | 2940 (31.8) | 2674 (27.3) | 1095 (27.5) | 188 (22.1) | 777 (24.7) | 262 (24.1) | 522 (26.3) | 6698 (30.1) |
| 2007–2012 | 13,305 | 71.3 | 9480 (33.3) | 1592 (34.7) | 3135 (33.9) | 3175 (32.4) | 1317 (33.1) | 261 (30.6) | 1158 (36.9) | 373 (34.4) | 677 (34.1) | 7272 (32.7) |
| 2013–2018 | 14,024 | 76.5 | 10,734 (37.7) | 1638 (35.7) | 3178 (34.3) | 3949 (40.3) | 1566 (39.4) | 403 (47.3) | 1206 (38.4) | 450 (41.5) | 784 (39.5) | 8294 (37.3) |
| AML subgroup | ||||||||||||
| APL | 3713 | 84.6 | 3141 (11.0) | 1086 (23.6) | 1298 (14.0) | 602 (6.1) | 131 (3.3) | 24 (2.8) | – | – | – | – |
| CBF AML | 1238 | 87.6 | 1085 (3.8) | 347 (7.6) | 407 (4.4) | 253 (2.6) | 66 (1.7) | 12 (1.4) | – | – | – | – |
| AML with antecedent C/T | 3009 | 65.9 | 1983 (7.0) | 111 (2.4) | 496 (5.4) | 888 (9.1) | 407 (10.2) | 81 (9.5) | – | – | – | – |
| All other AML | 32,195 | 69.2 | 22,264 (78.2) | 3048 (66.4) | 7052 (76.2) | 8055 (82.2) | 3374 (84.8) | 735 (86.3) | – | – | – | – |
AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CBF, core binding factor; C/T, condition/therapy; SEER-17, 17 cancer registry areas of the Surveillance, Epidemiology, and End Results Program; –, not applicable; <10, data with fewer than 10 cases are suppressed to protect patient confidentiality.
The SEER-17 registry areas are estimated to cover 26.5% of the U.S. population and those included in this study were the states of Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Mexico, New Jersey, Utah, and registries in areas of California (San-Francisco Oakland, San Jose–Monterey, Greater California, Los Angeles), Georgia (Atlanta, Greater Georgia, Rural Georgia) and Washington state (Seattle-Puget Sound). Refer to 'Methods' section for definition of initial chemotherapy.
Includes American Indian/Alaskan Native, other specified race, and unknown race.